Correlation of Ag-NOR protein measurements with prognosis in canine transmissible venereal tumour.
Ten canine transmissible venereal tumour (TVT) cases were studied by digital image analysis quantification on sections stained with silver to demonstrate nucleolar organizer regions (Ag-NORs). In each animal, 100 neoplastic cells were randomly selected for evaluation. The following parameters were measured or calculated: area of nucleus, area of Ag-NOR dot, the mean number of Ag-NOR dots per nucleus, the mean area of Ag-NOR dots per nucleus and the ratio of mean nuclear dot area to nuclear area. All 10 cases were treated with vincristine at a dose of 0.6 mg/m2 intravenously once a week. Two, which showed malignant characteristics (i.e. uncontrolled growth, local invasion or metastasis), did not respond to multiple (12) treatments and had a fatal outcome. Of the remaining eight cases, seven responded to two to six treatments and one required 12 treatments. The average number of Ag-NORs per nucleus and the area of Ag-NORs per nucleus were lower in the seven cases that responded to two to six treatments than in the other three cases, but the difference was not significant. However, there was a significant difference in the ratios of Ag-NOR area to nuclear area between the two groups of cases. Thus, poor prognosis was (1) possibly correlated with an increase in the mean number of Ag-NORs per nucleus and an increase in the mean area of Ag-NORs per nucleus, and (2) definitely correlated with an increase in the mean ratio of Ag-NOR area to nuclear area.
Harmelin
A
A
Koret School of Veterinary Medicine, Hebrew University, Jerusalem, Israel.
Zuckerman
A
A
Nyska
A
A
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis*; D004283:Dog Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D004285:Dogs; D009687:Nuclear Proteins / Q000032:analysis*; D009697:Nucleolus Organizer Region / Q000737:chemistry*; D011379:Prognosis; D016622:Silver Staining; D014685:Venereal Tumors, Veterinary / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D014750:Vincristine